Bicycle Therapeutics (NASDAQ:BCYC) Earns "Buy" Rating from HC Wainwright

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $33.00 price target on the stock. HC Wainwright's price target points to a potential upside of 200.82% from the company's current price. HC Wainwright also issued estimates for Bicycle Therapeutics' Q1 2025 earnings at ($0.99) EPS, Q2 2025 earnings at ($0.99) EPS, FY2025 earnings at ($3.90) EPS, FY2026 earnings at ($4.31) EPS, FY2027 earnings at ($3.45) EPS, FY2028 earnings at ($1.56) EPS and FY2029 earnings at $1.20 EPS.

BCYC has been the subject of a number of other research reports. Needham & Company LLC reaffirmed a "buy" rating and set a $32.00 price objective on shares of Bicycle Therapeutics in a research report on Monday, January 13th. JMP Securities cut their price objective on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a "market outperform" rating for the company in a research report on Wednesday, December 18th. B. Riley dropped their price target on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a "neutral" rating for the company in a research report on Friday, December 13th. Stephens reissued an "equal weight" rating and issued a $15.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, January 22nd. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $35.00 price target on shares of Bicycle Therapeutics in a research report on Friday, November 1st. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Bicycle Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $29.14.

Bicycle Therapeutics Trading Down 0.5 %

Bicycle Therapeutics stock traded down $0.06 on Wednesday, reaching $10.97. 275,772 shares of the stock were exchanged, compared to its average volume of 301,484. The stock has a market cap of $757.43 million, a PE ratio of -3.33 and a beta of 0.93. Bicycle Therapeutics has a twelve month low of $10.81 and a twelve month high of $28.67. The firm has a fifty day moving average price of $13.19 and a two-hundred day moving average price of $19.32.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.75) EPS for the quarter, beating analysts' consensus estimates of ($0.85) by $0.10. The business had revenue of $3.70 million during the quarter, compared to analyst estimates of $5.47 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The firm's revenue for the quarter was down 30.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.16) earnings per share. Equities analysts anticipate that Bicycle Therapeutics will post -3.06 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CAO Travis Alvin Thompson sold 2,686 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $15.00, for a total transaction of $40,290.00. Following the sale, the chief accounting officer now directly owns 32,146 shares of the company's stock, valued at $482,190. This represents a 7.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Kevin Lee sold 9,038 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total transaction of $127,345.42. Following the sale, the chief executive officer now directly owns 495,026 shares in the company, valued at $6,974,916.34. This trade represents a 1.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 27,677 shares of company stock valued at $392,413. 8.50% of the stock is currently owned by insiders.

Institutional Trading of Bicycle Therapeutics

Several hedge funds have recently modified their holdings of the stock. L & S Advisors Inc grew its stake in shares of Bicycle Therapeutics by 2.4% during the third quarter. L & S Advisors Inc now owns 59,735 shares of the company's stock valued at $1,352,000 after purchasing an additional 1,400 shares during the last quarter. Assetmark Inc. bought a new stake in shares of Bicycle Therapeutics during the third quarter valued at approximately $34,000. JPMorgan Chase & Co. grew its stake in shares of Bicycle Therapeutics by 26.8% during the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock valued at $191,000 after purchasing an additional 1,782 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Bicycle Therapeutics by 30.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company's stock valued at $131,000 after acquiring an additional 2,191 shares during the last quarter. Finally, Barclays PLC boosted its stake in Bicycle Therapeutics by 878.3% in the fourth quarter. Barclays PLC now owns 2,612 shares of the company's stock valued at $37,000 after acquiring an additional 2,345 shares during the last quarter. 86.15% of the stock is owned by institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.